tradingkey.logo

Oncolytics Biotech® Receives FDA Fast Track Designation For Pelareorep In 2L Kras-Mutant Mss Metastatic Colorectal Cancer

ReutersFeb 4, 2026 1:52 PM

- Oncolytics Biotech Inc ONCY.O:

  • ONCOLYTICS BIOTECH® RECEIVES FDA FAST TRACK DESIGNATION FOR PELAREOREP IN 2L KRAS-MUTANT MSS METASTATIC COLORECTAL CANCER

  • ONCOLYTICS BIOTECH INC - TO LAUNCH CONTROLLED STUDY IN SECOND-LINE KRAS-MUTANT MSS MCRC WITH INTERIM DATA EXPECTED BY END OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI